Showing results for 'D'
Total number of hits: 125
Click on results for more details:
PDIDOTH010
3,4-Dibenzoyl dopamine
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDB021
Bodor et al_08
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDB022
Bodor et al_09
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDB023
Bodor et al_10
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDB024
Bodor et al_11
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDB025
Bolazine
Active compound: Drostanolone
Indications: Na
Target: na
PDIDB026
Bolazine capronate
Active compound: Drostanolone
Indications: Na
Target: Androgen receptor
PDIDC026
CHEMBL1615593
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC027
CHEMBL1802093
Active compound: DOPAC
Indications: Lung, ovary and breast cancer
Target: Tyrosine kinases
PDIDC030
CHEMBL32085
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC032
CHEMBL497112
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC033
CHEMBL590229
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC034
CHEMBL598828
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC035
CHEMBL598829
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC042
Ciclesonide
Active compound: Desisobutyrylciclesonide
Indications: Asthma and allergic rhinitis
Target: Glucocorticoid receptor
PDIDC043
CID 10009229
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDOTH016
4-S-Cysteaminylphenol
Active compound: DTXSID30473723
Indications: Malignant melanoma
Target: Thymidylate synthase and DNA synthesis
PDIDC044
CID 10089832
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC045
CID 101239087
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC046
CID 101239088
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC047
CID 101239089
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC048
CID 101239091
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC049
CID 101239092
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC050
CID 101458753
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC051
CID 101681216
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC052
CID 101681217
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC053
CID 101681218
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC054
CID 102239065
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC055
CID 10439599
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC056
CID 10621768
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC057
CID 10937253
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC058
CID 11796118
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC059
CID 12004257
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC060
CID 129866160
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: GABA-benzodiazepine receptor (GABA-BZR) complex
PDIDC061
CID 129866166
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: GABA-benzodiazepine receptor (GABA-BZR) complex
PDIDC062
CID 129866179
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: GABA-benzodiazepine receptor (GABA-BZR) complex
PDIDC063
CID 129866181
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: GABA-benzodiazepine receptor (GABA-BZR) complex
PDIDC066
Cid 14756455
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC067
CID 20301216
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC068
CID 21390763
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC069
CID 21426279
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC070
CID 44267476
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC071
CID 44267505
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC074
CID 73317165
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC075
CID 74983874
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC076
CID 74983875
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC077
CID 75242292
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC078
CID 75242294
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC079
CID 75243316
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC080
CID 75243318
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC081
CID 75243320
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC082
CID 75243324
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC083
CID 75243326
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC084
CID 76723249
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC085
CID 76723253
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC086
CID 76723259
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC087
CID 85143503
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC088
CID 86157027
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDC096
Clobenzorex
Active compound: D-amphetamine
Indications: Attention deficit hyperactivity disorder (ADHD),obesity and a body mass index (BMI) of 30 kg/m2 or higher who have not responded to an appropriate weight-reducing regimen alone
Target: Sodium-dependent dopamine transporter
PDIDD001
Dabigatran Etexilate
Active compound: Dabigatran
Indications: Anticoagulant
Target: Prothrombin
PDIDD002
Dabigatran etexilate
Active compound: Dabigatran
Indications: Venous thromboembosis
Target: Prothrombin enzyme
PDIDD006
DC-81 prodrug
Active compound: DC-81
Indications: Cancer
Target: DNA minor groove
PDIDD007
D-Deprenyl
Active compound: D-methamphetamine
Indications: Na
Target: na
PDIDD007
D-Deprenyl
Active compound: D-amphetamine
Indications: Attention deficit disorder, hyperactivity and narcolepsy
Target: na
PDIDD009
Delamanid
Active compound: Delamanid- intermediates (still to-be-identified) (R6)
Indications: Tuberculosis
Target: Mycolic acid synthesis
PDIDD010
Delapril
Active compound: Delapril diacid
Indications: Hypertension and heart failure
Target: Converting enzyme inhibitor (CEI); ACE inhibitor
PDIDD014
Dextromethorphan
Active compound: Dextrorphan
Indications: Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma, cough
Target: Sigma non-opioid intracellular receptor 1; HCG20471, isoform CRA_c; Glutamate receptor ionotropic, NMDA 3A
PDIDD016
Di Stefano etal_2006_(+)-5
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDD019
Diethylstilbestrol diphosphate
Active compound: Diethylstilbestrol
Indications: Prostate cancer
Target: Estrogen receptor alpha; Estrogen receptor beta
PDIDD020
Diloxanide furoate
Active compound: Diloxanide
Indications: Asymptomatic (cyst passers) intestinal amebiasis; E. histolytica cysts
Target: Protein synthesis
PDIDD026
Docarpamine
Active compound: Dopamine
Indications: Refractory ascites
Target: Dopamine receptor D1
PDIDD027
DOPA cyclohexyl ester
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDD028
DOX-FCPPs-PyTPE
Active compound: Doxorubicin
Indications: Breast cancer, Bladder cancer and Cervical cancer
Target: DNA topoisomerase 2-alpha, DNA
PDIDD034
DTS-201
Active compound: Doxorubicin
Indications: Breast, colon, prostate, and lung cancers
Target: DNA topoisomerase 2-alpha
PDIDE021
Ethyl 2-acetamido-3-(3,4-diacetyloxyphenyl)propanoate
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDG002
Gamma-Ghb
Active compound: DTXSID10952728
Indications: Malignant melanoma
Target: Thymidylate synthase and DNA synthesis
PDIDG005
Gidazepam
Active compound: Desalkylgidazepam
Indications: Giddiness
Target: Benzodiazepine receptors in the CNS
PDIDH005
HMR 1826
Active compound: Doxorubicin
Indications: Necrotic tumors
Target: Beta-glucuronidase-positive cells
PDIDI005
Imipramine
Active compound: Desipramine
Indications: Depression
Target: Noradrenaline transporter (NET) reuptake inhibitor
PDIDI013
Isoxazolyl-prodrug of distamycin
Active compound: Distamycin
Indications: Na
Target: DNA topoisomerase 1; Estrogen receptor; GTPase Hras (WL1)
PDIDL001
L-377202
Active compound: Doxorubicin
Indications: Prostate cancer
Target: na
PDIDL011
Levodopa
Active compound: Dopamine
Indications: Parkinson's disease and dopamine-responsive dystonia
Target: Dopamine receptor D1, D2, D3, D4, D5 (WL 3)
PDIDL014
Lisdexamfetamine
Active compound: D-amphetamine
Indications: Attention Deficit Disorder With Hyperactivity (ADHD); Binge Eating Disorder (BED)
Target: Trace amine-associated receptor 1 (Drug Bank); Alpha-1B adrenergic receptor (Therapeutic Target Database)
PDIDL016
Loratadine
Active compound: Desloratadine
Indications: Seasonal allergic symptoms (R1)
Target: H1 histamine receptor
PDIDM010
Mestilbol
Active compound: Diethylstilbestrol
Indications: Menopause
Target: Estrogen receptor
PDIDM020
Midodrine
Active compound: Desglymidodrine (DMAE)
Indications: Dysautonomia and orthostatic hypotension
Target: Alpha-adrenergic receptors
PDIDM029
Moxisylyte
Active compound: Deacetylthymoxamine
Indications: Erectile dysfunction
Target: α1-adrenergic antagonist
PDIDA022
Acediasulfone
Active compound: Dapsone
Indications: Ear infection; Leprosy
Target: Dihydropteroate synthetase
PDIDN004
NB-355
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDP012
Peptide-doxorubicin prodrug
Active compound: Doxorubicin
Indications: Tumor
Target: na
PDIDQ001
Quercetin
Active compound: DOPAC
Indications: Lung, ovary and breast cancer
Target: Tyrosine kinases
PDIDA032
AKOS024372695
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDS005
SCHEMBL1068518
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDS006
SCHEMBL1069483
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDS007
SCHEMBL1070495
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDS008
SCHEMBL14377320
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDS009
SCHEMBL14764340
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDS012
SCHEMBL18259288
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDS014
SCHEMBL19730390
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: GABA-benzodiazepine receptor (GABA-BZR) complex
PDIDS015
SCHEMBL19730392
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: GABA-benzodiazepine receptor (GABA-BZR) complex
PDIDS016
SCHEMBL19730393
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: GABA-benzodiazepine receptor (GABA-BZR) complex
PDIDS017
SCHEMBL19730395
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: GABA-benzodiazepine receptor (GABA-BZR) complex
PDIDS018
SCHEMBL19730396
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: GABA-benzodiazepine receptor (GABA-BZR) complex
PDIDS019
SCHEMBL19730397
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: GABA-benzodiazepine receptor (GABA-BZR) complex
PDIDS020
SCHEMBL19730398
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: GABA-benzodiazepine receptor (GABA-BZR) complex
PDIDS021
SCHEMBL19730400
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: GABA-benzodiazepine receptor (GABA-BZR) complex
PDIDS025
SCHEMBL6372980
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDS028
SCHEMBL7441616
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDS030
SCHEMBL9356853
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDS045
Stenbolone acetate
Active compound: Dihydrotestosterone
Indications: Na
Target: Androgen receptor
PDIDA037
Aldoxorubicin
Active compound: Doxorubicin
Indications: Solid tumors
Target: DNA topoisomerase 2-alpha
PDIDT022
Testifenon
Active compound: Dihydrotestosterone
Indications: Tumor and Cancer
Target: Androgen receptor
PDIDD035
DNR-GA3
Active compound: Daunorubicin (DNR)
Indications: Ovarian cancer
Target: DNA
PDIDD036
DOX-GA3
Active compound: Doxorubicin (DOX)
Indications: Bladder, breast, lung, stomach, and ovarian cancer
Target: DNA
PDIDOTH007
1-Androsterone
Active compound: Dehydroepiandrosterone
Indications: Potential chemopreventive activity,immunologic adjuvants
Target: na
PDIDA050
Androstanolone benzoate
Active compound: Dihydrotestosterone
Indications: Na
Target: Androgen receptor
PDIDA051
Androstanolone enanthate
Active compound: Dihydrotestosterone
Indications: Na
Target: Androgen receptor
PDIDA052
Androstanolone propionate
Active compound: Dihydrotestosterone
Indications: Na
Target: Androgen receptor
PDIDA053
Androstanolone valerate
Active compound: Dihydrotestosterone
Indications: Na
Target: Androgen receptor
PDIDA059
Artemisinin
Active compound: Dihydroartemisinin
Indications: Malaria
Target: Heme present in the hemozoin and hemoglobin; histidine-rich protein II (PfHRP II)
PDIDA060
Artesunate
Active compound: Dihydroartemisinin
Indications: Malaria
Target: Malaria proteins EXP1
PDIDA064
Avizafone
Active compound: Diazepam
Indications: Anxiolytic agent and muscle relaxant,premediation for anesthesia, a sedative for minor surgery or invasive procedures, and for treatment of status epileptus or severe recurrent seizures
Target: Acetylcholinesterase
PDIDOTH009
3,4-Bis(ethoxycarbonyloxy)benzeneethanamine
Active compound: Dopamine
Indications: Parkinson’s disease (PD)
Target: Dopamine receptor
PDIDB011
Benzphetamine
Active compound: d-Amphetamine
Indications: Attention deficit hyperactivity disorder (ADHD)
Target: Sodium-dependent dopamine transporter; Synaptic vesicular amine transporter
PDIDB014
Bezitramide
Active compound: Despropionyl-bezitramide
Indications: Severe chronic pain
Target: na